TEVIMBRA Received FDA Approval as First-Line Therapy for Gastric …
Dec 28, 2024 · The prognosis for patients with gastric or GEJ cancer depends on the stage at diagnosis, treatment response, and overall health. Immunotherapies, such as TEVIMBRA …
FDA Approves Tevimbra Combination for Gastric or …
Dec 30, 2024 · Tevimbra is a type of precision cancer medicine. This humanized IgG4 anti-PD-1 monoclonal antibody was designed specifically to minimize binding to FcγR on macrophages. …
Tevimbra Plus Chemo May Be Safe, Effective in Advanced Gastric/GEJ Cancer
Feb 3, 2025 · Tevimbra plus POFI demonstrated high efficacy with a 93.5% objective response rate and 100% disease control rate in advanced gastric cancer. Median progression-free …
FDA Approves Tislelizumab Plus Chemo for PD-L1+ Unresectable …
Dec 27, 2024 · Key Takeaways. Tislelizumab-jsgr (Tevimbra) approved for first-line treatment of HER2-negative gastric or GEJ adenocarcinoma with PD-L1 expression.
FDA Approves Tislelizumab-jsgr (Tevimbra) Combo for Gastric or ...
Dec 30, 2024 · The U.S. Food and Drug Administration (FDA) approved tislelizumab-jsgr (Tevimbra) in combination with chemotherapy as a first-line treatment for adults with …
TEVIMBRA® (tislelizumab-jsgr) for Gastric or Gastroesophageal …
Treatment of gastric cancer often uses endoscopic resection, which may be curative in the early stages of the disease. Given the high rate of relapse, neoadjuvant and adjuvant chemotherapy …
FDA Approves Tislelizumab/Chemo in Gastric/GEJ Adenocarcinoma
Dec 27, 2024 · The FDA previously accepted a biologics license application BLA for tislelizumab plus chemotherapy to treat patients with locally advanced or metastatic gastric or GEJ …
Tevimbra Approved in U.S. for First-line Treatment of Gastric and ...
Dec 27, 2024 · The additional indication for first-line G/GEJ cancers is based on results from BeiGene’s RATIONALE-305 (NCT03777657), a randomized, double-blind, placebo-controlled, …
Beigene Tevibra Approved in US for Gastric Cancer Treatment
Dec 30, 2024 · The FDA approved BeiGene's TEVIMBRA (tislelizumab-jsgr), combined with chemotherapy, for first-line treatment of advanced HER2-negative gastric or gastroesophageal …
FDA Approves Tevimbra as First-Line Treatment for Gastric …
Dec 31, 2024 · Additionally, it is use as a first-line treatment for locally advanced, unresectable, or metastatic ESCC is being evaluated under a separate biologics license application (BLA) …
- Some results have been removed